Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver
Requires Subscription or Fee PDF

Keywords

biologics
data exclusivity protection
Trans-Pacific Partnership Trade Agreement

Abstract

Biopharmaceutical research and development is overwhelmingly focused in the U.S. becasue here it is incentivized and encouraged through a robust intellectual property rights protection environment.  Across the board, the United States provides the most comprehensive, effective intellectual property rights protections for biopharmaceuticals.  As a result, the industry locates here, researches here, and thrives here.  With an acknowledgement of the importance of intellectual property rights as well as the wider benefits of biopharmaceutical research and development, it's tremendously disappointing that the recently negotiated Trans-Pacific Partnership (TPP) Trade Agreement fails to deliver sufficient IP protections for biologics.  This article explores the importance of a rigorous intellectual property environemtn for the biopharmaceutical industry through an examination of the importance of data exclusivity provisions.  Such protection is critical as the number, complexity and cost of clinical trials increases.  Technology inevitably evolves faster than the legal architecture that surrounds it.  As technology evolves, making the development of new biologic vaccines and therapies possible, society's commitment to incentivize innovation and protect it must be enshrined in the intellectual property protections of agreements such as the TPP.
https://doi.org/10.5912/jcb731
Requires Subscription or Fee PDF

References

Adams, C.P. and V.V. Brantner. “Spending on New Drug Development,†Health Economics, vol.19, no.2, February 2010, pp.130-141.

Battelle. “Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies,†March 2015. Available at: http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf

Budish, Eric, Benjamin N. Roin, and Heidi Williams. “Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,†American Economic Review, vol.105, no.7, 2015, pp.2044-2085.

Calmes, Jackie. “Utah Senator, Crucial Ally for the Pacific Rim Trade Deal, Is Now Its Main Hurdle,†New York Times, 12 November 2015. Available at: http://www.nytimes.com/2015/11/13/us/politics/utah-senator-crucial-ally-for-the-pacific-rim-trade-deal-is-now-its-main-hurdle.html

Cohen, Wesley M., Richard R. Nelson, and John Walsh. “A First Look at the Results of the 1994 Carnegie Mellon Survey of Industrial R&D in the United States,†unpublished manuscript, 28 February 1996.

Cohn, Meredith. “Industry funds six times more clinical trials than feds, research shows,†The Baltimore Sun, 15 December 2015. Available at: http://www.baltimoresun.com/health/bs-hs-trial-funding-20151214-story.html

Desmon, Stephanie. “Industry-financed clinical trials on the rise as number of NIH-funded trials falls: Researchers raise concerns about trends in research funding as commercial ventures run six times more trials than academic investigators,†The HUB at Johns Hopkins, 16 December 2015. Available at: http://hub.jhu.edu/2015/12/15/industry-funded-clinical-trials-may-threaten-objectivity

DiMasi, Joseph A. and Henry G. Grabowski. “The Costs of Biopharmaceutical R&D: Is Biotech Different?†Managerial and Decision Economics, vol.28, 2007.

Getz, K.A., R.A. Campo, and K.I. Kaitin. “Variability in Protocol Design Complexity by Phase and Therapeutic Area.†Drug Information Journal, 2011, vol.45, no.4, pp. 413–420.

Grabowski H.G. and J.M. Vernon. “A New Look at the Returns and Risks to Pharmaceutical R&D,†Management Science, vol.36, no.7, 1990, p.804-821.

Grabowski, H.G., J.M. Vernon and J.A. DiMasi. “Returns on research and development for 1990s new drug introductions,†Pharmacoeconomics, vol.20, suppl.3, 2002, pp.11-29.

Grabowski, Henry, Genia Long and Richard Mortimer, “Data Exclusivity for Biologics,†Nature Reviews: Drug Discovery, January 2011, vol.10, pp.15-25. Available at: http://www.nature.com/nrd/journal/v10/n1/suppinfo/nrd3277.html

Levin, R.C., A.K. Klevorick, R.R. Nelson, and S.G. Winter. “Appropriating the Returns from Industrial Research and Development,†Brookings Papers on Economic Activity, (Special Issue), no.3, 1987, pp.783-831.

Lybecker, Kristina. “IP Protection for Biologics in the TPP: Trading Away Future Treatments and Cures,†IPWatchDog, 26 October 2015. Available at: http://www.ipwatchdog.com/2015/10/26/ip-protection-for-biologics-in-the-tpp-trading-away-future-treatments-and-cures/id=62692/

Mansfield, Edwin. “Patents and Innovations: An Empirical Study,†Management Science, vol.32, no.2, February 1986, pp.173-181.

Mansfield, Edwin, Mark Schwartz, and Sam Wagner. “Imitation Costs and Patents: An Empirical Study,†Economic Journal, vol.91, no.364, December 1981, pp.907-918.

Mossinghoff, Gerald J. “Encouraging Invention and Innovation: The Key to Human Progress,†PhRMA: Pharmaceutical Research and Manufacturers of America, World Wide Web Posting: January 1998. [www.phrma.org/issues/inter1.htm]

Mossinghoff, Gerald J., and Thomas Bombelles. “The Importance of Intellectual Property Protection to the American Research-Intensive Pharmaceutical Industry,†Columbia Journal of World Business, vol.XXXI, no.1, Spring 1996, pp.38-48.

Mossinghoff, Gerald J. “Research-Based Pharmaceutical Companies: The Need for Improved Patent Protection Worldwide,†Journal of Law and Technology, vol.2, no.2, 1987, pp.307-324.

Peretz, S. Michael. “Pharmaceuticals in the Third World: The Problem from the Suppliers’ Point of View,†World Development, vol.11, no.3, March 1983, pp.259-264.

PhRMA (Pharmaceutical Research and Manufacturers of America). “2015 Biopharmaceutical Research Profile†online post, 2015. Available at: http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf

PhRMA(Pharmaceutical Research and Manufacturers of America). “Biopharmaceuticals in Perspective,†Spring 2013. Available at: http://www.slideshare.net/PhRMA/phrma-chart-pack-april-2013?related=1

Roy, A.S.A. “Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials,†Project RDA Report, 24 April 2012. Available at: https://www.manhattan-institute.org/html/stifling-new-cures-true-cost-lengthy-clinical-drug-trials-6013.html

Santoro, Michael. “Pfizer: Global Protection of Intellectual Property,†Harvard Business School Case Study N9-392-073, April 6, 1995.

Scherer, F.M. “The Economic Effect of Compulsory Patent Licensing,†Monograph Series in Finance and Economics, New York, NY: New York University, 1997.

Smith, N. Craig. “Note on Pharmaceutical marketing Practices In the Third World,†Harvard Business School Case Study N9-590-032, December 16, 1990.

Smith, N. Craig. “Ciba-Geigy Pharmaceuticals: Pharma International,†Harvard Business School Case Study N9-589-108, December 14, 1990.

Taylor, C.T., and Z. A. Silberston. The Economic Impact of the Patent System. Cambridge, UK: Cambridge University Press, 1973.

Tocker, Edwin. “A Chemical Industry Perspective,†Chapter 13 in Intellectual Property Rights and Capital Formation in the Next Decade, Charls E. Walker and Mark A. Bloomfield, eds., pp.151-162, Landham, MD: University Press of America, Inc., 1988.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.